Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer

British Journal of Cancer

Volumn 101, Issue 6, 2009, Pages 992-997

  Lomholt, A F ^a   Hoyer Hansen G ^b   Nielsen, H J ^a   Christensen, I J ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Colorectal cancer; Detection; UPAR

Indexed keywords

CITRIC ACID; UROKINASE RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL FEATURE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENDOSCOPY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 70249112937     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605228     Document Type: Article

References (37)

1. Almasi CE, Hoyer-Hansen G, Christensen IJ, Dano K, Pappot H (2005) Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 48:349-355
2. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40 Bond JH (2003) Colon polyps and cancer. Endoscopy 35: 27-35
3. Burch JA, Soares-Weiser K, St John DJ, Duffy S, Smith S, Kleijnen J,Westwood M (2007) Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 14:132-137
4. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M,Romer J (2005) Plasminogen activation and cancer. Thromb Haemost 93: 676-681
5. Duffy MJ, van DA, Haglund C, Hansson L, Holinski-Feder E, Klapdor R,Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360
6. Eur J Cancer 43: 1348-1360 Ellis V, Scully MF, Kakkar VV (1989) Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937monocytes. J Biol Chem 264: 2185-2188 (Pubitemid 19057691)
7. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007)Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592 (Pubitemid 46359643)
8. Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K,van d V, Verheijen JH, Lamers CB, Verspaget HW (1996) Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77: 1035-1043
9. Ganesh SJ, Sier C, Heerding M, Griffioen G, Lamers C, Verspaget H (1994)Urokinase receptor and colorectal cancer survival. The Lancet 344: 01-402
10. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G (2008) leaved forms of the urokinase plasminogen activator receptor in plasma ave diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 14: 5785-5793
11. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2006) Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev, Issue 4: Art. No: CD001216
12. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420: 79-85
13. Hoyer-Hansen G, Lund IK (2007) Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 44: 65-102
14. Hoyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Dano K, Behrendt N (2001) Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 358: 673-679
15. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K (1992) Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267: 18224-18229
16. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56: 104-132
17. Konno H, Abe J, Kaneko T, Baba M, Shoji A, Sunayama K, Kamiya K, Tanaka T, Suzuki S, Nakamura S, Urano T (2001) Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 92: 516-523
18. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ, for the American Cancer Society Colorectal Cancer Advisory Group tUM-STFatACoRCCC (2008) Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58: 130-160 (Pubitemid 351830299)
19. Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Menez A (2005) Crystal structure of the human urokinase plasminogen ctivator receptor bound to an antagonist peptide. EMBO J 24: 1655-1663
20. Mustjoki S, Sidenius N, Sier CFM, Blasi F, Elonen E, Alitalo R, Vaheri A (2000) Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 60: 7126-7132
21. Nielsen HJ, Brunner N, Frederiksen CB, Lomholt AF, King D, Jørgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurgberg S, Christensen IJ (2007) Plasma tissue inhibitor of metalloproteinases-1(TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol 43(2): 242-248
22. Ohtani H, Pyke C, Dano K, Nagura H (1995) Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 62: 691-696
23. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global Cancer Statistics, 2002. CA Cancer J Clin 55: 74-108
24. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675
25. Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano K, Hoyer-Hansen G, Lilja H (2006) Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 52: 838-844
26. Piironen T, Laursen B, Pass J, List K, Gardsvoll H, Ploug M, Dano K, Hoyer-Hansen G (2004) Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 50: 2059-2068
27. Ploug M, Behrendt N, Lober D, Dano K (1991) Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost 17: 183-193
28. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K (1994) Immunohistochemical detection of the receptor for urokinase lasminogen activator in human colon cancer. Histopathology 24: 131-138
29. Ransohoff DF (2007) How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 60: 1205-1219
30. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Hoyer-Hansen G, Smith K, Brunner N, Harris AL (2002) Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 8: 1132-1141
31. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to Prognosis. J Natl Cancer Inst 91: 869-874
32. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365: 153-165
33. Werb Z (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442
34. Wilhelm OG, Wilhelm S, Escott GM, Lutz V, Magdolen V, Schmitt M, Rifkin DB, Wilson EL, Graeff H, Brunner G (1999) Cellular glycosylpho- sphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 180: 225-235
35. Winawer SJ, St JJ, Bond J, Hardcastle JD, Kronborg O, Flehinger B, Schottenfeld D, Blinov NN (1990) Screening of average-risk individuals for colorectal cancer. WHO collaborating centre for the prevention of colorectal cancer. Bull World Health Organ 68: 505-513 (Pubitemid 20295581)
36. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329: 1977-1981
37. Zhou HM, Nichols A, Meda P, Vassalli JD (2000) Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 19: 4817-4826